

Philip Livingston and Friedhelm Hellung
U.S. Serial No.: 08/477,147
Filed: June 7, 1995
Page 2

On page 5, line 15, please delete "(a)" and insert -- (Figure 3A) -
--.

On page 5, line 15, please delete "(b)" and insert -- (Figure 3B) -
--.

On page 5, line 30, please delete "(a)" and insert -- (Figure 6A) -
--.

On page 5, line 31, please delete "(b)" and insert -- (Figure 6B) -
--.

On page 7, line 17, after "IgM", please insert -- (Figure 10A) --.

On page 7, line 17, after "IgG", please insert -- (Figure 10B) --.

On page 114, line 16, please wrap "(by logrank test). A similar trend was seen for survival (p = .08 by logrank test)." after ".02."

In the claims:

Please cancel claim 45 without prejudice.

In accordance with 37 C.F.R. §1.121(b), please amend claims 44, 46 and 47 by adding the underlined material and deleting the bracketed material as follows:

--44. (Amended) A method for stimulating or enhancing in a subject production of antibodies which recognize a ganglioside comprising administering to the subject an effective dose of a vaccine comprising an amount of ganglioside, which is selected from the group consisting of GM2, GM3, GD2, GD3, GD3 lactone, O-Acetyl GDB and GT3, or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.--